In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi Sankyo Co. Ltd.

Latest From Daiichi Sankyo Co. Ltd.

Daiichi’s Quizartinib And The Quintessential 'Pazdur Moment'

Daiichi Sankyo made a strong case to rebut US FDA’s concners about the “credibility” of a survival benefit reported for its refractory AML therapy quizartinib in front of the US Food & Drug Administration’s Oncologic Drugs Advisory Committee. Then Richard Pazdur spoke.

Advisory Committees Clinical Trials

Penalty For Daiichi As It Falls Short In Japan Flu Vaccine Project

Japanese firm fails to meet production capacity target under Japan national flu vaccine supply plan, triggering a financial penalty and the return of government grant money.

Japan Vaccines

Pharma ‘Making Progress’ On Medicines Access, But Gaps Remain

A new report says that the 20 major companies in the Access to Medicines Index have made progress in areas like inclusive business models, R&D prioritization and equitable pricing, but not enough is being done to develop new medicines for less profitable diseases or to support flexibilities such as compulsory licensing.
International Business Strategies

Pink Sheet Podcast: Oncology Reviews, Biosimilars, and More Biosimilars

Our discussion of US FDA's two-drug Oncologic Drugs Advisory Committee meeting, the recent biosimilar insulin public hearing, and the new final biosimilar interchangeability guidance.
Advisory Committees Biosimilars
See All

Company Information